Targeted treatment of Active Pharmaceutical Ingredients (APIs) and Pharmaceutical residues
A major asset in the sustainable delivery of your products, removing concerns of operational downtime due to water treatment failures
Reduces water intake and wastewater discharge, saving substantial operational cost
Pharmaceutical products are released into wastewater streams from manufacturing sites and drug development bases across the world.
The production and use of a comprehensive portfolio of pharmaceutical products results in the discharge of wastewater with a complex composition. Due to this, pharmaceutical wastewater is often hard to treat in order to comply with strict regulations.
As water is used as an ingredient in many formulations and for cleaning purposes in the pharmaceutical sector, this usually results in high volumes of wastewater being transported or treated.
Studies show that Active Pharmaceutical Ingredients (APIs) and pharmaceutical residues, even at trace levels in treated wastewater, are having detrimental effects on aquatic species and potentially human health. This is because traditional wastewater treatment processes are not designed to tackle such varied and persistent compounds which results in the contaminants eventually entering the environment and even sources used for drinking purposes.
Arvia’s patented Nyex™ treatment systems provide a highly reliable and targeted treatment of APIs and pharmaceutical residues from wastewater, ensuring the maintenance of legislative standards for discharge. We are also working with several forward-thinking global pharmaceutical manufacturers wanting to deploy an advanced tertiary process to effectively remove antibiotics from their wastewater. Although in many cases, this is not a regulatory requirement, organisations are anticipating upcoming regulations due to the research conducted on Antimicrobial Resistance (AMR) and the severity of this issue rendering medication ineffective.
Our systems are modular in nature, which means they can be scaled to meet your flow rate requirements. This also means that it can be easily adapted to tackle new regulations, emerging contaminants and extension or seasonal alteration of production lines.
The Nyex™ processes do not require chemical dosing, produce any secondary waste and can be powered by solar energy, providing a more sustainable treatment option.
Nyex™ treated wastewater can be safely reclaimed and reused for other purposes within the business, saving money and addressing high water demands in times of shrinking supplies.
We understand that pharmaceutical companies pride themselves on quality customer care, ensuring patients encounter minimal barriers to treatment. Nyex™ treatment plays a major part in the sustainable delivery of your products and Arvia guarantee that your organisation can continue to develop and supply essential medicines without the concern for operational downtime due to water treatment failure.
Probably the biggest problem facing policymakers tackling pharmaceuticals in the environment (PiE) is that they are invisible. If it is difficult to persuade people that they should change age-old practices and make costly investments....